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DRUG DISCOVERY IN TUBERCULOSIS: A MOLECULAR APPROACH
Partha P. Mitra*
Summary: Despite unquestionable success of the combination drug therapy, tuberculosis (TB) very recently has drawn major
attention because of the global upsurge of MDR-TB, XDR –TB and HIV-TB co-infection cases. In the last four decades, only
one compound is added to the treatment regimen leaving ample opportunities to find out a new generation of TB drugs. The
modern concept of drug discovery utilizes the integrated knowledge of genomics, proteomics, molecular biology and systems
biology to identify more specific targets. The purpose of this review is to revisit the field of tuberculosis drug discovery based
on those new concepts to identify novel targets.
*Senior Research Officer, Research Wing, Diamantina Institute, Princess Alexandra Hospital, University of Queensland, Level 4, 20 Cornwall
Street, Woolloongabba, Queensland - 4102 (Australia).
INTRODUCTION
TB had been considered as one of the most
fatal diseases to the human race long before Robert
Koch discovered the staining technique to detect the
responsible bacilli Mycobacterium tuberculosis
(M.Tb).  From the beginning of seventeenth century
until World War-II, several parts of Europe, America
and Japan suffered from the TB epidemic with the
consequence of death of several million people1.
However, a major breakthrough in the TB treatment
came after introducing streptomycin, followed by
p-aminosalicylic acid (1949), isoniazid (1952),
pyrazinamide (1954), cycloserine (1955),
ethambutol (1962) and rifampin (rifampicin; 1963)
as an effective primary line of anti-TB drugs. Single
drug treatment in TB has however, several
drawbacks which include prolonged treatment time
to completely eradicate the bacteria as well as
increasing the opportunity to develop drug- resistant
TB bacilli which has been documented in almost
every country where the disease is prevalent.
Although pulmonary TB related death has  declined
sharply in the western world since the beginning of
the 20th century,  it still causes major health hazards,
especially in Asia, Africa and the Western Pacific
region. In the beginning of 1980s, increase in TB
related mortality raised a global health concern mainly
because a) drug-resistant Mycobacterium and b)
opportunistic infection of TB bacilli in the
immunodeficiency condition as a result of HIV
infection. Present gold-standard treatment for TB is
a six-month course of rifampicin and isoniazid,
supplemented in the initial two months with
pyrazinamide in association with either ethambutol
or streptomycin. Persons with latent TB infection
are treated with isoniazid for six months 2. The
current success rate using cocktail drug is about
95% and is effective on drug-susceptible M.Tb
provided the patient completes the six to nine month
treatment period. Fixed dose combination (FDC) is
one of the WHO recommended optimal drug
treatments for TB in order to reduce treatment time,
cost and perhaps to reduce the risk of emergence of
drug resistant mycobacterium 3. However, any
difficulties of FDC treatment can generate chronically
contagious cases, which may excrete drug-resistant
mycobacteria 4. The Directly Observed Treatment
Short-course (DOTS) and DOTS-Plus programmes
are recommended by WHO to control TB by
providing  a comprehensive organizational and
infrastructural framework for the rational use of
diagnosis, drug supply, as well as case and
programme management services. DOTS-Plus
accommodates additional second-line TB drugs to
the people presumed to get MDR-TB 5. Recently,
TB due to Multi drug resistant (MDR-TB) and
extensively drug resistant (XDR-TB) strains gave a
wakeup call to the global health organization agencies
to organize the TB programme and reinstate a fresh
effort to develop a new drug against the pathogen.
According to WHO, about 650,000 cases of MDR-
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TB have been reported worldwide in 2010, among
them 9% are estimated to be XDR-TB cases. At
present, globally, the fatality rate due to MDR-TB
infection is about 30%.  A syndemic relationship has
been reported in HIV and MDR-TB. In 2010, about
3,50,000 people died of HIV-associated TB and 25%
of deaths due to HIV are associated with TB6. The
global scenario of TB related health hazard is not
only pointing to a major loophole of the management
of TB programme but also indicating an urgent need
to develop new drugs or new combinations of drugs
to save the lives of millions of people worldwide.
This review aims to shed some light on to redirect
our approach to discover a new TB drug by utilizing
recent advancements in this field.
CURRENT OPINION ON TB DRUG
DEVELOPMENT
TB treatment has been standing in the same
strategic point which was started almost five decades
ago. Cocktail drug therapy, the most widely accepted
TB treatment, though effective, but has a prolonged
treatment time and is inefficient to control disease
progression in MDR-TB and HIV-TB co-infected
patients. Current trends in anti-TB drug development
are mainly driven by three major factors: a)
development of drugs with long lasting
antimycobacterial activity in vivo is desirable as
because it will be helpful to bypass the problem of
non–adherence and thus can reduce the risk of
emergence of MDR and XDR-TB cases, b)
development of novel compounds to combat MDR-
TB and XDR-TB is urgently needed. c) a new class
of anti-TB drugs will be very promising for
prevention of latent infection or eradication of slowly
metabolizing or dormant populations of
mycobacterium bacilli 7,8. Companies investigating
on new anti-TB drugs have been deterred by a
number of constraints which include a) insufficient
animal models that closely mimic the human TB; b)
difficulties in demonstrating the obvious benefit of a
new anti-TB agent over pre-existing drugs, since
multi-drug combination therapy is highly effective
against ordinary cases of TB; c) perceived lack of
commercial return to companies as the disease is
mostly prevalent in developing countries and the cost
is less than US$13 for the whole course of treatment.
Anticipating the success of combination therapy, more
reports are coming out in the last few years addressing
the efficacy of such therapeutic approach. For
example, clinical studies carried out very recently in
South Africa with patients suffering from drug sensitive
and MDR-TB showed a promising result. A
combination of  PA-824{(6S)-2-nitro-6-{[4-
(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine}-moxifloxacin-
pyrazinamide has been shown to be very effective in
reducing the early bacterial count in the sputum of the
treated patient9.Global TB Alliance and Bayer AG very
recently replaced Isoniazid by Moxifloxacin in the
cocktail of the combination drug therapy which is
reported to reduce the treatment time by two months
in mice10.  Currently, this combination is in human
clinical trials in several geographical regions around
the world including the cases of HIV-TB deadly co-
infection and results are expected soon. At present, a
combination of antiretroviral therapy and rifampin has
been considered as the back bone of treatment of HIV-
TB cases11. Such efforts to improve the efficacy of
combination treatment regimen created a novel example
of low-risk drug discovery profile rather than focusing
on to develop a completely new stand alone molecule
against TB which should be either more cost effective
than the existing drug and/or reduce significantly the
treatment time. In spite of the success of combination
therapy in the field of TB, several new drugs are
currently in the development pipeline to come out as a
single drug therapy in TB treatment. Among them, novel
drugs such as TMC207, SQ109 and sudoterb [LL3858]
have produced most promising results. Besides that,
gatifloxacin and moxifloxacin; linezolid, PNU100480
and AZD5847; metronidazole, OPC-67683 and PA-824
are currently considered as very promising next
generation TB drugs12,13.  According to the latest WHO
global report, list of such drugs and their status in the
clinical trials are summarized in Table-1. Though the
initial reports of these current pipeline of drugs are
very promising, but the increasing global threat of
MDR-, XDR-TB and HIV-TB have created a new niche
for the development novel drugs in this field. Therefore,
updated knowledge in the field on novel compound
sources, methods of target validations, molecular
models and animal proof of concept, which will be
discussed in next several sections, can be
implemented to find new drugs in the field of TB.
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NOVEL COMPOUND RESOURCE
Classically, any drug discovery process
starts with the finding of a set of novel compounds,
considered as hits, from a compound collection
defined as library. Such a kind of library is built up
based on collection of compounds from a wide
variety of sources which may include small
molecules with novel scaffold and unknown function,
molecules originated from natural sources like
secondary metabolites of plants and marine habitats.
Recently, researchers are utilizing libraries with
several thousands molecules of defined structure for
the identification of hits in the field of targeted drug
discovery. For example, the crystal structure of any
key enzyme can be utilized for precise designing or
understanding of the scaffold of competitive
inhibitors. Similarly, interaction between two proteins
either essential for host pathogen interaction or to
drive any key metabolic pathway can be targeted to
design a molecule which can interfere with the
interaction. In silico searching, either competitive
inhibitors for any enzyme or inhibitors of protein-
protein interaction in any such library is now-a-days
a routine job for drug discovery research. Until
recently, not too much attention was paid to the
natural sources, for example, marine sources, to
search for novel compounds against Mycobacteria.
There are several unique reasons why marine
resources should be explored for searching novel
compounds such as  a) very wide biodiversity and
largely unexplored environment (80% of all life
forms on Earth are present only in the oceans),
b) uniqueness and diversity at the genetic level
(Sponges: >100 000 genes and Humans: ~25 000
genes). Two commercially available antivirals Ara-
A (acyclovir) and AZT (zidovudine) were isolated
from sponge14 and c) large chemical diversity
(marine organisms often incorporate halogens like
F, Cl, Br, I into their chemical structures which are
rarely seen in terrestrials). Marine organisms are also
a rich source of a very wide variety of bio-reactive
molecules like phenols, terpenoids, fatty acids,
polysaccharides, proteins, acetylenes, terpenes,
indole derivatives, and antimicrobial peptides. Several
such compounds like saturated 2-methoxylated FA
from sponges and secondary marine microbial
metabolites like pseudopyronines were evaluated
successfully for growth inhibitory effect of
mycobacterium 15, 16. In collaboration with academic
institutions, several companies are searching for
novel antimycobacterial agents from a repository
built up with the extract of wide variety marine
organisms. Besides searching for novel compounds
against mycobacterium from natural products and
secondary metabolites, genetic chemistry may be a
completely new generation source to synthesize
novel compounds with unique scaffolds. Several
natural products like alkaloids, terpens, alkanes,
alkenes, alkynes, phenolics and acetogenic quinones
have shown antimycobacterial activity 17. As a stand
alone compound, they showed mild activity but
became a potential agent when they were put in
combination 18, 19. Taking the advantage of Genetic
Chemistry technology, we can synthesize several
of such small molecules which are not exposed to
the nature. Genes involved in the pathway of
producing small molecules can be collected from a
wide variety of different species like sponges,
bacteria, human, fungi and plants and will be allowed
to go through recombination in vivo. By combining
and evolving genes from different organisms, genetic
chemistry has laid a novel in vivo platform of
combinatorial chemistry and enables the discovery
of unique and novel chemical identity which never
existed in nature. Drug discovery companies are
currently working on several disease models as a
target to utilize this technology20.
Phase-I Phase-II Phase-III 
AZD5847  
 
TMC-207 
OPC-67683 
PA-824 
Linezolid 
Rifapentine 
SQ-109 
PNU-100480 
Novel 
Regimensa 
Gatifloxacin 
Moxifloxacin 
Rifapentine 
Table 1: List of latest drugs* and their status in
the clinical trials.
* They are used as single drug or in combination or used as a
replacement drug in the existing cocktail therapy.
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TARGETS IN ANTI-TB DRUG DEVELOPMENT
Very recently, several attempts were made
to identify new molecules against TB utilizing a wide
variety of model systems which include inhibitors
of enzymes critical for bacterial metabolic pathways,
cell wall synthesis inhibitors, signaling pathway
inhibitors21-25. However, several such attempts are
no doubt far less than sufficient and required more
attention to develop a new therapeutic approach
utilizing the genomic as well as the systems biology
information, as drug resistant TB and TB in a HIV
patient created a new paradigm of global health
concern. A successful drug discovery programme
against TB should include a novel molecular model
system which will be unique to the bacteria and
should be targeted independently without affecting
the host system. Targeting enzymes in a metabolic
pathway is a classical approach to inhibit the bacterial
growth but the major limitation here is frequent
development of resistance. Isoniazid, an inhibitor of
the mycolic acid pathway enzyme InhA (an enoyl
reductase), is used for the primary line of TB therapy.
Patients who undergo treatment for the MDR-TB
have shown a very high rate of mutation in this
enzyme 26, 27. Other enzymes such as FabH (â-
ketoacyl-acyl carrier protein synthase III) that play
a very important role in mycolic acid biosynthetic
pathway, have   drawn recent attention as a fresh
drug target28.  Using structure-based drug designing
technology, it is possible to develop very high affinity
inhibitors which can be helpful for circumventing
the normal mechanism of mutation mediated drug
resistance 29. Cyclopropane synthases have been
shown to be implicated in pathogenicity and therefore
constitute attractive targets for the development of
new drugs against TB 30. In M.Tb, genes cmaA2,
mmaA2 or pcaA encode enzymes that are involved
in the cyclopropanated mycolic acid synthesis, are
well characterized and has not been explored in
targeted drug discovery31. Latent infection is another
major health concern in TB prevalent zones and about
one third of the world population is estimated to be
latently infected. During this asymptomatic phase
of infection, Mycobacterium is partly capable of by
passing the host immune system with the formation
of granulomas32. Recent data show two enzymes in
the glyoxalate shunt pathway, isocitrate lyase and
malate synthase play an important role in the growth,
persistence and support granuloma formation in
host33, 34. Subsequently, those enzymes are considered
as targets to carry out highthroughput searches to
find out potential new enzyme inhibitors. Although
many potential new drug targets have been identified
and their number is increasing with time therefore,
more effort is required in target validation to show
unequivocally that they are specifically acting upon
the bacterial growth and survival.
APPROACH TO TUBERCULOSIS DRUG
DISCOVERY
During the period of the last two decades,
the cost of drug discovery has increased  several
fold partly  to meet the increasingly complicated
criteria of the regulatory authority. A recent survey
on the costs of the research and development of 68
randomly selected new drugs from ten
pharmaceutical firms shows an increase in capital
costs at an annual rate of 7.4% above general price
inflation35. Even simple arithmetic suggests that the
costs of discovering new chemical entities have been
climbed up more than four fold in the last two
decades. An attempt at TB drug discovery combines
several steps and an exit point should be attached to
each step to rationalize the cost of the whole
discovery process. The three stage approach for drug
discovery and development against M.Tb  should
consist of a) highthoroughput, low cost, time saving
assay using nonpathogenic mycobacterium, b) lead
optimization using pathogenic organism like M.Tb
and finally, c) test on appropriate animal model to
check in vivo efficacy and pharmacokinetics before
we reach  the stage of human clinical trials. Initial
screening, in case of targeted drug discovery, should
include a collection of several molecules using
optimized reporter based assay system and generated
hits will follow lead optimization stage and onwards.
Highthoroughput, low cost time saving assay
using non-pathogenic mycobacterium
Mycobacterium can be classified into two
major categories depending upon their growth in
vitro, one is fast growing, non-pathogenic organism
and another is slow growing, pathogenic organism.
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Slow growing pathogenic mycobaterium will be a
difficult organism to screen a large number of targets
in a very short period of time and particularly at the
same time when one of our main objectives is to
develop molecules which will preferentially have
antimycobacterial activity. Therefore, a preference
was given to use M. smegmatis mainly because a) it
is non-pathogenic and easy to handle b) growth rate
of M. smegmatis is almost eight times faster than
M.Tb, and it is widely used to understand the biology
of M.Tb such as cell culture, gene expression and
persistence in the face of nutrient starvation c) most
importantly, M. smegmatis was found to display a
profile similar to MDR M.Tb36-39. Therefore, cell
viability assay could serve as a ‘surrogate’ for MDR
M. TB. The main goal of this primary assay is to
help in prioritizing the compounds which can be
tested further in more specific in vitro assays on
pathogenic M. TB, MDR and XDR strains. There
are several reports on the use of M. smegmatis in
primary screening to select compounds which could
be active against M. TB40-43. It was reported that the
susceptibility of M. smegmatis for the two frontline
anti-TB drugs, isoniazid and rifampicin, was identical
to that of MDR clinical isolates of M. tb. The
specificity of the M. smegmatis based on screening
has to be extremely specific so that hits generated in
this assay can be a potential target for both normal
as well as MDR strains.
Targeted drug discovery focusing on validation
of the molecular models
Classically targeted drug discovery can be
subdivided into several major categories which
include a) protein-protein interaction, b) inhibitors
of key regulatory enzymes, c) antimicrobial peptides,
d) antisense RNA, e) siRNA. Our discussion will be
focused mostly on first three categories as others
have not yet come out as major potential areas,
particularly in the field of TB.
a) Protein-protein interaction
A network of protein-protein interaction
controls a wide variety of biochemical and cellular
processes from bacteria to metazoan.  Small
molecules impair such interactions have  emerged
as a drug-like inhibitors and recently several such
interactions for a variety of disease models going
through the screening process44.  A number of
protein-protein interactions (PPIs) network have been
proposed for M.Tb45. Disrupting such PPIs using
small molecules will create new opportunities for
utilizing non-traditional strategies as therapeutics.  A
fluorescence based highthroughput protein-protein
interaction model has been described in Fig. 1. In
this assay, the two interacting proteins were taged
with two different fluorescence molecules such as
Cyan Fluorescent Protein (CFP) and Yellow
Fluorescent Protein (YFP).  During interaction,  they
are close enough to pass the energy from one
fluorescent protein to another. In the presence of
inhibitors, the energy transfer will be inhibited. This
Fluorescence Resonance Energy Transfer (FRET)
assay has been considered a routine practice in
recent days of drug discovery research.
b) Inhibitors of enzymes
As described earlier, enzymes of
mycobactrial origin can always be considered as
major targets for drug discovery. The major
drawback of enzyme inhibitors is that the bacterial
cell can easily develop resistance against those
inhibitors. At present, several enzymes have been
considered as potential targets and some of them
are listed in Table-2. Though inhibitors of several
enzymes are already tested to check the binding
efficiency, however much of the cases can be
designed based on the crystal structure of the protein.
Active site structure of the enzyme can be determined
if the enzyme is crystallized in the presence of a
substrate. As well as aiding rational design methods,
the detailed structure of the enzyme and the binding
position and orientation of ligands allow computer-
based drug design methods, such as docking, to be
used to screen and identify likely enzyme inhibitors.
The basic procedure of computer assisted drug
discovery (CADD) has been described in Fig. 2,
where virtual hits can be identified by utilizing in
silico docking system.
To accomplish docking studies, the native
3D structure of the target protein must be known,
typically using X-ray crystallography and virtual
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Target Reference 
Maltosyltransferase Kalscheuer R, et al. Nat Chem Biol. 
May;6(5):376-84.  2010 
PhosphoriboPhosphoribosylpyrophosphate 
Synthetase 
Lucarelli AP, et al. 
PLoS One. Nov 15;5(11):e15494, 2010. 
ATP phosphoribosyltransferase ChoY, et al, J.lMed. Chem., 51,(19), 2008. 
Thymidylate Kinase Familiar O, et al,  Chem Med Chem 3,(7),2008 
Protein Tyrosine Phosphatase B Mϋller-Noren A, J. et al, Angewandte Chem. Int. 
Ed. 47,(32), 2008. 
DNA gyrase Manjunath a, Nuc. Acids Res. 33 (10) 2005. 
Cyclopropane synthase Glickman, MS; Mol. Cell, Vol. 5, April, 2000. 
Glycosyltransferases Lucas, R, Chem Bio Chem, 9, 2008. 
Lysine ε-aminotransferase      Dube, D., Med. Chem. Res. 17(2-7) 2008 
Table 2: List of recent drug targets on mycobacterium
All recently identified targets and references listed above are enzymes of a wide variety of metabolic activity.
*include the mycolic acid biosynthetic pathway enzymes
 FRET signal can be generated when two interacting proteins, playing a central role in the mycolic acid biosynthetic
pathway, are cloned and overexpressed in the yeast with two different fluorescent tags like YFP and CFP. Such
genetically engineered yeast population can be considered as screening machinery to identify novel small
molecules originated either from genetic chemistry or from natural sources.
Figure 1: Reverse yeast two hybrid based HT assay models*
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compound libraries can then be docked in the active
site. Careful examination of the results will evaluate
their binding capacities and allow the discovery of
potential inhibitors. An alternate method can be to
design inhibitors based on the blue print of the
transition state structure. The strongest interaction
between the enzyme and the substrate occurs at the
transition state of a enzyme substrate reaction and
therefore, though it is challenging to identify the
intermediate transition state analogues, but it can be
an alternative to design a strong binding affinity
inhibitor(s) 46,47.
c) Antimicrobial peptides
Alveolar macrophages and lung epithelial
cells are the first cells that encounter M. Tb.
Respiratory secretions have microbicidal and
microbiostatic properties mediated by their
constituent antimicrobial peptides. á- and b-
defensins, mainly produced by neuotrophil and
various epithelial cells, have been well studied in
linking the acquired and innate immunity. The
expression of short peptide like defensin is tightly
regulated by the NF-êB and requires activation of
Toll-like receptor 2 (TLR2)-mediated intracellular
signaling pathway. Direct killing of bacilli by
antimicrobial peptides as well as to the increased
penetration of drugs into the mycobacterium present
inside the macrophages, make antimicrobial peptides
as potential candidates for the treatment of TB. The
effect of combination of antimicrobial peptides and
conventional anti-mycobacterial drugs (e.g. isoniazid
and rifampicin) has been evaluated against M. Tb
H37Rv in vitro, ex vivo, and in vivo, and it has been
observed that the effective therapeutic dosage of
conventional antiTB drugs could be reduced
approximately to half by supplementing antimicrobial
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Virtual Screening
Crystal Structure Protein Chemical Library
Virtual Hits
Live Mycobacterium
Anti-Bacterial Assay
Killed Mycobacterium
Crystal structure of several crucial proteins of Mycobacterium origin can be used for virtual screening of chemical
libraries with indication of antibacterial activity. Such a process, known as molecular docking, may be a novel
approach to find out new potential molecules. Screened molecules catalogued based on the binding energy can
be tested for antimycrobial activity.
Figure 2: Virtual screening on chemical library using crystal structure of metabolically active proteins
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peptides in the therapeutic schedule. Therefore,
antimicrobial peptides can be used as adjunct
chemotherapy with conventional drugs against
human TB48,49.
LEAD IDENTIFICATION
Monocyte infection Assay
Identification of hits using non-pathogenic
mycobacterium should be tested on their pathogenic
counterparts to check the efficacy of those
compounds. The test is important for lead
optimization and validation because several
fundamental differences exist between pathogenic
and non-pathogenic strains, particularly in metabolic
pathways, membrane transportations, and regulation
of gene expression as well as more prominently on
macromolecules responsible for the pathogenicity.
More importantly, all those factors may determine
either independently or collectively the response of
these organism against a particular molecule with
therapeutic potential. For example, M. Tb has only
five recognizable carbohydrate transporters in the
inner membrane, while M. smegmatis has
twentyeight such transporters at its disposal 50.
Similarly, it was found that protein tyrosine
phosphatase ptpAt (a virulence factor for M. tbs and
contributes to its survival within host macrophages)
promoter is a highly active in slow-growing species
of mycobacteria, such as M. tb and M. bovis BCG,
but inert in fast-growing mycobacterial species, such
as M. smegmatis 51. Strong evidence is in favour of
the fact that the nature of mycolic acid plays a crucial
role in determining the fluidity and permeability of
mycobacterial cell wall. M.tb modify their mycolic
acids by cyclopropanation, whereas fast-growing
saprophytic species M.smegmatis do not, indicating
that this modification may be associated with the
adaptation of this organism to oxidative stress52.  M.
Tb synthesizes three major types of cyclopropanated
mycolic acids through the action of five putative
homologous cyclopropane synthases and some of
them  have been shown to have mycolic acid
cyclopropanating activity when introduced into M.
smegmatis, do not produce cyclopropanated mycolic
acids 31,53-54. The biochemical and the macro
molecular differences between the pathogenic and
non-pathogenic mycobacterium create a major
challenge for taking forward of non-pathogenic hits
to the pathogenic test. All evidences, therefore,
clearly indicate that compounds which show activity
in the M.smegmatis may not necessarily work on
M.tb. The interaction between macrophage and
M.Tb. is a critical step in the establishment of an
early chronic infection. Because of these obvious
differences, there is a dire need to confirm the activity
of the compounds in pathogenic M.tb in vitro using
cell based assay such as Monocyte Infection Assay
(MIA). MIA is a quick and very established assay
model to understand infection mechanism in vitro
by M.tb. Monocytes is a host of both HIV and
Mycobacterium and it has been reported that after
infection with M.tb, monocytes enhanced HIV-1
replication55,56. Asymptomatic mycobacterium
infection can lead to the disease syndrome under
immunodeficiency condition followed by HIV
infection. Therefore, hits established in this model
can be extrapolated from the single mycobacterium
infection to the co-infection model system.
Patient PBMC assay
Efficacy of hits against mycobacterium can
be tested further in ex vivo before they go through
the animal proof of concept. Peripheral Blood
Mononuclear Cell (PBMC) isolated from tubercular
patients can be considered as a very good ex vivo
model particularly in a country where TB is widely
prevalent. Test on collections of wide variety of
patient samples in different stages of the infection
with different strains of mycobacterium (MDR or
XDR) will reveal the efficacy of the compound in
diverse spectrum of disease situation. Several studies
in animal models indicate that a series of immuno
pathological event happen followed by mycobaterium
infection. For example, infected cells from active TB
patients showed significant production of nitric oxide
as compared to that of uninfected cells57-59 . Elevation
in the level of IFN-gamma is also observed in human
PBMC infected with M.Tb. A gross downregulation
of gene expression associated with innate and adaptive
immunity are observed in animal model infected with
M.Tb. A lower relative expression of key innate
immunity related genes including the Toll-like receptor
(TLR2,4) genes, lack of differential expression of
PARTHA  P.  MITRA
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indicator adaptive immune gene transcripts (IFNG, IL2,
IL4) and lower major histocompatibility complex class
I (BOLA) and class II (BOLA-DRA) gene expression
was consistent with innate immune gene repression in
the BTB-infected animals58‘. This wide array of
differential gene expression pattern will certainly
influence the effect of the functionality of drugs in
PBMC isolated from patients in comparison to the
normal human counterpart. Therefore, hits tested on
MIA followed by the patient PBMC assay before
exploring the animal model system will be more
informative and cost-effective.
Animal efficacy model
The murine model has been considered as a
central tool for the elucidation of protective immune
mechanisms that are essential for controlling M. Tb
infection. Additionally, the study of inbred mice has
revealed significant divergence in the susceptibility
and disease progression of individual mouse strains
to an infection with M. Tb60-61. The continued study
of genetically disparate mouse strains has the
potential to identify immune mechanisms that
correlate with increasing susceptibility to TB. These
mechanisms will be highly applicable to studies in
men and will assist in the early detection of
individuals that are more vulnerable to the
development of reactivation of TB. Also murine
models of TB have the advantages of low cost,
availability of immunological reagents, and the choice
of inbred populations with varying susceptibility to
aerosol infection62-64.  Murine models for TB give
the power to detect the differences in duration of
therapies. Therefore, considering all those facts,
mouse remains the most popular in vivo model for
testing small molecules for their potential.
DRUG  DELIVERY
Research on drug delivery is mainly driven
by the two major factors, one is the targeted delivery
where drug will be navigated to the diseased tissue
and second is sustained release formulation where
drug will be released in a controlled fashion. An ideal
TB drug formulation should satisfy both of those
parameters so that bioavailability of the drug to the
targeted tissue in one hand is upregulated and
controlled and on the other hand uniform release of
the drug will reduce the chance of developing MDR
and XDR-TB cases. Liposome encapsulated drug
delivery is one of the recent attempts to increase the
bioavailability and tissue specific distribution of TB
drugs. Single intravenous dose of modified liposomes,
loaded with rifampicin and isoniazid, targeted to
deliver drugs in alveoli, maintain the plasma/tissue
drug level for five-seven days. A significant reduction
in bacterial count was reported when mice were
going through a weekly dose for six consecutive
weeks in comparison to the same dose of free drug
treatment. Chemotherapeutic activity against murine
TB using once weekly administered drugs such as,
isoniazid and rifampicin, encapsulated in liposomes,
augment several fold the antibacterial activity of those
two drugs65. Recent evidence shows that nanoparticle
based drug delivery will replace all those existing
methods  because of high carrier capacity, stability,
independence on the route of administration and
feasibility of restricted release form the matrix.
Frontline TB drugs like rifampicin, isoniazid and
pyrazinamide show a significant effect when
encapsulated with nanoparticles66-68.
POST GENOMIC ERA AND SYSTEMS
BIOLOGY IN DRUG DISCOVERY
Unveiling genome sequence of M.tb H37Rv
in 1998 opens altogether a completely new horizon
in the field of drug discovery. Though the bacilli
harbour an estimated 4000 genes, about 52% of the
predicted proteins have known functions and 376
putative proteins can be considered as unique to the
organism because there is no apparent sequence
homology with the existing data bases69 . With the
help of functional genomics, if some of them are
detected as essential for the survival, then those
macromolecules can be considered as a novel drug
target for M.tb. Since the complete genetic
information is also available for the non-pathogenic
strains like M.smegmatis therefore, comparative
genomics will provide a new outlook on the
differential gene expression patterns across the
strains. Comparison of gene expression arrays among
the drug sensitive and drug resistance organism
would reveal a significant clue regarding
macromolecules responsible for the phenotype of
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the organism and thus can generate new targets for
anti-TB drug discovery70-72. Databases like
GenoMycDB, comprise pair-wise sequence
alignments of the protein coding sequences collected
from five different pathogenic mycobacterium. A
comparison of such data bases would be an added
advantage to identify pathogen specific genes and
can be used as a drug target for any particular class
of mycobacterium73 . Identification of genes
supports the latency of the organism and can also
have a significant implication in TB drug development.
Recent studies on genes related to the latency of the
organism identified isocitrate lyase and gene regulator
ó-factor (SigF).  Another study on amphibian TB
model shows that genes with polymorphic PE-PGRS
repeats are related to the granuloma formation, a
stage associated with the chronic mycobacterium
infection. Genes with the tandem PE-PGRS repeat
encode a set of unique, exceptionally glycine and
alanine rich protein located mostly on the surface of
the mycobacterium and thought to be responsible
for the pathogenesis. However, vaccination using
those proteins failed to protect mice against TB
infection most likely indicating the antigenic variation
of PE-PGRS repeat genes74. Therefore,
pathogenicity of mycobacterium does not solely
depend on the regulation of a particular class of gene
expression rather it may be a cumulative effect of
several classes of stage specific gene expressions
and thus justifies a highthoroughput global gene search
to identify novel genes related to determine virulency
and latency of the organism.
Recent introduction of systems biology in
the field of drug discovery created a new niche to
understand the overall regulatory network at the level
of cells, tissues, organs and the organism. This
emerging field has the potential to generate a specific
molecular model as a target. Based on the
computational modeling and predictive simulation, it
will be very effective for identifying the control point
of a molecular network which can be targeted for
the drug discovery75-77 . Integration of genome wide
data on several molecules like mRNA, proteins and
metabolites will provide a logical picture of their
cellular behaviour. M.tb transcriptome complies the
information of global analysis of gene expression
under different conditions which would enable us to
identify expression of stage specific gene and the
products of those differentially expressed genes can
also be considered as a subject of drug targets.
Protein-protein interaction network, interactome,
encompasses a variety of interaction like physical
association of two proteins critical for the metabolic
pathway or interaction needed to make biologically
active complex. After analysis of the interaction
network, Raman K et al78 identified several critical
drug targetable protein-protein interactions based on
novel algorithm. One of the classical examples is the
interaction of proteins drive the mycolic acid
biosynthetic pathway. Presence of mycolic acid,
arabinogalactan-mycolate covalently linked with
peptidoglycan and trehalose dimycolate in the cell
wall provides an extra protection to this organism to
survive in the hostile phagolysosomal environment
within macrophage, antibiotic treatment as well as
help them to evade the host immune system. In silico
analysis based on the recent biochemical as well as
genetic information identifies InhA, AccD3, Fas,
FabH, Pks13, DesA1/2, and DesA3 proteins are
competent for the drug targets and it was also
reported that FabH-InhA interaction is critical in the
FAS-II biosynthetic pathway. A highthoroughput co-
immunoprecipitation assay or Yeast-two-hybrid based
assay, such as FRET assay can be very effective
model for target assisted drug discovery. Therefore,
system analysis of interaction network and global
analysis of comparative gene expression using omics
(Transcriptome, Reactome, Interactome) can
highlight potential novel targets in TB drug
discovery79.
CONCLUSION
Development of new drugs in the field
of TB continues to be more challenging because
of the emergence of drug resistance organisms
as well the cases of the opportunistic
mycobacterium infection in HIV patients. On the
other hand, crystal structures of proteins or
enzymes, unrevealing mycobacterium genome
sequence as well as systems biology have opened
a new horizon in the field of drug discovery.
Researchers, at this cross road, are facing an
additional challenge in the field of the cost of
new drug discovery, finding new therapy cheaper
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than the existing treatment regimen and
developing any new drug which will significantly
reduce the treatment time. On the other hand,
the molecular basis of drug discovery in the field
of TB is very much in the rudimentary stage.
In this review, focus was given on the molecular
basis of drug discovery based on the recent
information available in the field of molecular,
cell and systems biology in the field of TB. As an
example, a unique model of drug discovery based
on protein-protein interaction was proposed
where interacting proteins as well as the
interaction is playing a critical role in the
synthesis of cell surface molecule, mycolic acid,
required for the pathogenesis of this organism.
Target selection, conceptualized on the recent
systems biology information, includes docking
on unique enzymes related to pathogenicity such
as cyclopropane synythetase, would be another
potential model in the field of anti-TB drug
discovery.
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